spacer
home > ebr > autumn 2003 > upping the anti - keeping ahead of antibiotic resistance
PUBLICATIONS
European Biopharmaceutical Review

Upping the Anti - Keeping Ahead of Antibiotic Resistance

The prevalence of antibacterial resistance seems to be rising, yet few new antibiotics have been approved in recent years. How dire is the situation and what is Enanta doing to address it?

Drug resistance is continually increasing and the supply of new antibiotics has slowed. Resistance to antibiotics varies by geographic region and there is no doubt that clinically important species of bacteria such as Streptococci, one of the major causes of respiratory tract infections, have developed resistance to more than one antibiotic. A recent study completed by the Centers for Disease Control in the US concluded that by next year 40 per cent of Streptococci will be resistant to both penicillins and macrolides.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Aimee Dingwell, News Editor at BioCentury Publications Inc, talks to Spiros Jamas, President and CEO of Enanta

Dr Spiros Jamas graduated from the University of Manchester Institute of Science and Technology, England, in 1981 with a BSc (Hons) in Chemical Engineering. He also holds a MSc in Food Science and Technology and a PhD in Biotechnology from the Massachusetts Institute of Technology.

In 1988, Dr Jamas founded and served as President, CEO and Director of Alpha-Beta Technology, a company that developed medical applications of carbohydrates. During his tenure at Alpha-Beta, he was instrumental in raising $200 million through venture capital, as well as public financings. Dr Jamas has also directed two INDs, five Phase I, three Phase II, and two Phase III clinical trials, while concurrently acquiring another privately held biotechnology company. Following this, he held the position of President and CEO of Repair Inc, a biopharmaceutical company that developed sustained-release angiogenesis therapies for the repair of diseased organs and tissues.

Dr Jamas has served as President and CEO of Enanta since the company's inception in 1999, providing scientific and business leadership.

spacer
Aimee Dingwell
spacer
spacer
spacer
Dr Spiros Jamas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Synpromics announces a research collaboration with GE Healthcare to extend the toolbox for production of biologics

Edinburgh, UK, 4th January 2017 – Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a research collaboration with GE Healthcare to jointly develop customised synthetic promoters optimised for GE Healthcare’s proprietary biopharmaceutical manufacturing platform.
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 
Industry Events

5th Biennial Biosimilars & Biobetters Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global are proud to present our highly anticipated 5thBiennial Biosimilars & Biobetters Congress, 16th – 17thApril 2018, London, UK. Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions will enjoy over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement